The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Now, it’s worth noting Stock Advisor’s total average return is 975 % — a market-crushing outperformance compared to 193% for ...

Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.

The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Novo Nordisk carries a Zacks Rank #5 (Strong Sell), whereas Amgen carries a Zacks Rank #3 (Hold) at present, which makes AMGN ...

Relief rally underway in Novo Nordisk after a difficult year for the stock which saw it lose ground to arch-competitor Eli ...

On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare.

Novo Nordisk shares surged Tuesday after the company said it received FDA approval for an oral version of its injectable weight-loss drug Wegovy.

Pharma giant Novo Nordisk's stock jumped over 7% during the stock market session on 23 December 2025, after the company's ...

Novo Nordisk A/S is rated a Buy with improved execution and valuation gap with LLY to drive outperformance through 2026. Read ...

Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk‘s (NYSE:NVO) Wegovy weight-loss pill, the first of its kind. This once-daily tablet uses the same active ingredient — ...